Page 235 - Read Online
P. 235

Missale et al. Hepatoma Res 2018;4:22  I  http://dx.doi.org/10.20517/2394-5079.2018.72                                            Page 3 of 15


               PD-1 is expressed by activated T and B lymphocytes, NK cells, Treg cells, MDSCs, monocytes and DCs [24,25] .
               The expression of PD-1 is induced by several cytokines including IFN-γ [26,27] . Under hypoxic conditions,
               production of hypoxia-inducible factor (HIF)-1 induces the expression of PD-L1, the PD-1 ligand, in MDSCs
               and tumor cells [22,27,28] . The interaction between PD-1 and PD-L1 inhibits T cell effector function and leads to
                              [29]
               T cell exhaustion . The immune infiltrate of HCC is enriched in PD1+ CD8+ cells and their abundance is
                                           [30]
               associated with disease prognosis . The expression of PD-L1 in HCC has also been reported as a prognostic
               factor of shorter disease-free and overall survival [31-34] .

               TIM-3 is a transmembrane protein expressed on various immune cells and interacting with multiple ligands
                                                                                          [35]
               among which galectin-9, a soluble protein expressed by several tissues including liver  that negatively
                                                                                                     [37]
                                       [36]
               regulates Th1 cell function . In addition, TIM-3+ Treg cells exhibit enhanced suppressor activity . A
               role of the TIM-3/galectin-9 pathway in the determination of HCC-infiltrating T cell dysfunction has been
                      [38]
               reported .
               LAG-3 binds MHC class II molecules with high affinity [25,39]  thus reducing co-stimulatory function of DCs.
                                                       [40]
                                                                                        [41]
               LAG-3 is upregulated upon activation of T cells  and is a marker of exhausted T cells . Its activation and,
               as a consequence, its blockade are synergistic with PD-1 [42,43] . BTLA is upregulated on activated lymphocytes
                                                                  [44]
               and on tumour-specific CD8+ T cells in patients with cancer . High expression of the BTLA ligand HVEM
               (herpesvirus entry mediator) has been reported in patients with HCC and is associated with reduced
                                                     [45]
               lymphocyte infiltration and poorer prognosis .
               Cytokines are membrane-bound or secreted proteins involved in the regulation of immune cell function,
               inflammation and angiogenesis. Their pleiotropic roles include pro- and anti-inflammatory functions. CD4+
               T helper cells produce either Th1 cytokines [e.g., interleukin (IL)-1, IL-2, IL-12, IL-15, tumor necrosis factor
               (TNF)-α and IFN-γ] usually defined pro-inflammatory, or Th2 cytokines (e.g., IL-4, IL-8, IL-10 and IL-5)
                                                     [46]
               mainly exerting anti-inflammatory functions .
               Increased levels of IL-10 and TGF-β and reduced levels of IFN-γ have been detected in plasma from HCC
                      [47]
               patients . In liver tissue IL-10 is produced by DCs, KCs, HSCs, LSECs, MDSCs and T cells, inducing tol-
                                                                                         [50]
               erance [48,49] . Tolerogenic effect of IL-10 is linked to inhibition of CD4+ T cell activation  and, as a conse-
                                                   [51]
               quence, of cytotoxic CD8+ T-cell function . In addition IL-10 further interferes with T cell activation by
                                                                           [52]
                                                                                          [53]
               downregulating the expression of MHC-II and CD80/CD86 on APCs  and of NF-kB , a transcription
               factor strongly implicated in inflammatory responses. Despite its immunosuppressive activity in the context
               of inflammation, several studies report an immune-stimulatory role of IL-10 on CD8+ T-cell and NK-cell
               cytotoxic activity in experimental tumor models [54-56] .
               TGF-β, produced by parenchymal and non-parenchymal liver cells, is implicated in the maintenance of liver
                                 [57]
               immune homeostasis  and may exert a suppressive function towards anti-tumor immune reaction. TGF-β
               inhibits the expression of the transcription factors T-bet and GATA3, essential for the conversion of naive
               CD4+ T cells into Th1 and Th2 CD4+ T cells, respectively [58,59] . Conversely, TGF-β induces the differentiation
               of naive CD4+ T-cells into Tregs, inhibits the differentiation of naive CD8+ T cells to effector cells [60,61]  and
                                                                                          [62]
               decreases perforin and IFN-γ expression, further impairing cytotoxic CD8+ T-cell activity .
               Cell-mediated immune suppression
               Immune evasion of tumor cells may be linked to altered antigen processing and presentation, deriving from
                                                                            [63]
               HLA class I downregulation or from 2 microglobulin mutation/deletion . HLA class I expression is essen-
                                                                                   [64]
               tial for antigen presentation to CTLs and for tumor cell recognition by NK cells . Tumor cell elimination
               by NK cells may be also impaired by decreased expression of the NKG2D ligand ULBP1 that correlates with
                                    [65]
               early recurrence of HCC . Another mechanism of HCC immune evasion from NK cell killing has been
   230   231   232   233   234   235   236   237   238   239   240